

November 7, 2023

The Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, 5th Floor, Plot No. C/1  
G Block, Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400 051

Dept. of Listing Operations  
**BSE Limited,**  
P J Towers, Dalal Street,  
Mumbai -400001, India

Symbol: YATHARTH

Scrip Code: 543950

**Sub: Outcome of Board Meeting for Quarterly/Half Yearly Financial Results.**

**Ref.: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir / Madam,

In continuation to our earlier letter dated October 31, 2023, we wish to inform that the board of directors ("Board") of the Company at their meeting held today i.e. November 7, 2023, inter-alia, have approved unaudited standalone & consolidated financial results ("Financial Results") of the Company for quarter/half year ended September 30, 2023, based on the recommendation of Audit Committee.

Financial Results together with respective limited review reports issued by R. Nagpal Associates, chartered accountants, statutory auditors of the Company are enclosed as Annexure.

The Board meeting commenced at 03.15 PM (IST) and concluded at 4.55 PM (IST).

This disclosure will also be hosted on Company's website viz. [www.yatharthhospitals.com/](http://www.yatharthhospitals.com/)

Kindly take the same on record.

Thanking you,

Your faithfully,  
For Yatharth Hospital and Trauma Care Services Limited



**Ritesh Mishra**  
**Company Secretary & Compliance Officer**  
**Mem. No. A51166**  
Enclosed: As above

**Registered Office**

JA-108, DLF Tower A, Jasola District Centre, New Delhi - 110025

Tel: 011-49967892

**Corporate Office**

HO- 01, Sector - 01, Greater Noida West, 201306

Tel: 08800797947 | Fax: 0120-2973444 | Email: [cs@yatharthhospitals.com](mailto:cs@yatharthhospitals.com)

**Our Hospitals**

📍 Sector 110, Noida, Uttar Pradesh-201304

📍 Sector Omega -01, Greater Noida, Uttar Pradesh-201308

📍 Sector -01, Greater Noida West, Uttar Pradesh-201306

📍 Orchha-Jhansi Madhya Pradesh-472246

🌐 [www.yatharthhospitals.com](http://www.yatharthhospitals.com)



Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of **Yatharth Hospital & Trauma Care Services Limited** pursuant to Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**To the Board of Directors of  
Yatharth Hospital & Trauma Care Services Limited**

1. We have reviewed the accompanying Statement of Unaudited Standalone financial results of **Yatharth Hospital & Trauma Care Services Limited** (the Company) for the quarter and half year ended 30<sup>th</sup> September 2023 together with the notes thereon (hereinafter referred to as "the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("IND AS 34"), prescribed under section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India and is in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditors of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain



moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statements prepared in accordance with the recognition and measurement principles laid down in IND AS 34, prescribed under section 133 of the Act as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirement of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatements.

For R. Nagpal Associates  
Chartered Accountants  
Firm Registration No. 002626N



(CA. Rohit Mehra)  
Partner  
Membership No. 093910



UDIN: 23093910BGUGKC3730  
Place: Noida  
Date: 07<sup>th</sup> November 2023

# YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITED

UNAUDITED STANDALONE BALANCE SHEET AS AT SEP 30, 2023

(all amounts in Rs. millions, unless otherwise stated)

Particulars	Figures as at Sep 30, 2023	Figures as at March 31, 2023 (Audited)
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, Plant and Equipment	1,164.42	1,171.19
Capital work in progress	13.74	-
Right-of-use of assets	24.59	35.12
Financial Assets		
(i) Investments	468.83	468.83
(ii) Loan to subsidiary company's	1,910.46	-
(ii) Other Financial Assets	11.06	7.40
Other Non Current Assets	131.12	6.41
<b>Total non-current assets</b>	<b>3,724.22</b>	<b>1,688.94</b>
<b>Current assets</b>		
Inventories	32.60	32.20
Financial Assets		
(i) Trade receivables	1,265.24	858.27
(ii) Cash and cash equivalents	794.11	121.55
(iii) Bank Balance other than (ii) above	2,206.14	5.82
Current Tax assets (Net)	49.40	57.27
Other Current assets	256.42	498.27
<b>Total current assets</b>	<b>4,603.91</b>	<b>1,573.38</b>
<b>Total Assets</b>	<b>8,328.13</b>	<b>3,262.33</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity Share Capital	858.50	655.17
Other Equity	7,038.06	1,106.11
<b>Equity attributable to the owners of the company</b>	<b>7,896.56</b>	<b>1,761.28</b>
<b>Non-current liabilities</b>		
Financial liabilities		
(i) Borrowings	25.59	759.54
(ia) Lease Liabilities	5.31	15.91
(ii) Other financial liabilities (net)	56.10	56.10
Provisions	12.24	9.62
Deferred tax liabilities (Net)	43.26	42.97
<b>Total non-current liabilities</b>	<b>142.50</b>	<b>884.15</b>
<b>Current liabilities</b>		
Financial liabilities		
(i) Borrowings	39.29	376.74
(ia) Lease Liabilities	20.95	20.45
(ii) Trade payables		
(a) Total outstanding dues of Micro Enterprises and Small Enterprises	11.17	9.10
(b) Total outstanding dues of creditors other than Micro Enterprises and Small Enterprises	75.32	98.90
(iii) Other financial liabilities	79.84	90.64
Other current liabilities	61.92	20.50
Provisions	0.57	0.57
<b>Total current liabilities</b>	<b>289.07</b>	<b>616.90</b>
<b>Total Equity and Liabilities</b>	<b>8,328.13</b>	<b>3,262.33</b>



*Ag*

# YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITED

Regd. Office : JA 108 DLF Tower A NA Jasola District Centre South Delhi DL 110025 India

Corporate Office: HO-01, Sector-1 Greater Noida West Gautam Buddha Nagar UP 201306 India

Website: www.yatharthhospitals.com

Email: cs@yatharthhospitals.com

CIN : U85110DL2008PLC174706

## STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER/ HALF YEAR ENDED 30TH SEPTEMBER, 2023

(Rs. in Million except Shares and EPS)

Particulars	Standalone					
	Quarter Ended			Half Year Ended		Year Ended (Audited )
	30 Sep'2023	30 June'2023	30 Sep'2022	30 Sep'2023	30 Sep'2022	31 March'2023
<b>I</b> Revenue from operations	1,101.23	1,023.43	941.71	2,124.66	1,773.79	3,715.14
<b>II</b> Other income	33.46	3.96	4.53	37.43	7.28	15.95
<b>III Total Income (I+II)</b>	<b>1,134.69</b>	<b>1,027.40</b>	<b>946.24</b>	<b>2,162.09</b>	<b>1,781.06</b>	<b>3,731.08</b>
<b>IV Expenses</b>						
Medical consumables and pharmacy items consumed	224.56	186.26	168.09	410.83	319.13	624.32
Employee benefits expense	179.06	167.68	165.80	346.74	295.88	604.53
Finance costs	15.66	24.23	18.05	39.89	37.26	87.37
Depreciation and amortisation	31.66	31.60	28.44	63.25	55.99	126.45
Other expenses	384.69	378.57	339.48	763.26	659.96	1,433.21
<b>Total expenses (IV)</b>	<b>835.63</b>	<b>788.34</b>	<b>719.86</b>	<b>1,623.97</b>	<b>1,368.22</b>	<b>2,875.88</b>
<b>V Profit / (loss) before exceptional items and tax (III-IV)</b>	<b>299.06</b>	<b>239.06</b>	<b>226.37</b>	<b>538.12</b>	<b>412.84</b>	<b>855.21</b>
<b>VI Exceptional items (net)(Gain)/Loss</b>	-	-	-	-	-	-
<b>VII Profit / (loss) before tax (V-VI)</b>	<b>299.06</b>	<b>239.06</b>	<b>226.37</b>	<b>538.12</b>	<b>412.84</b>	<b>855.21</b>
<b>VIII Tax expense</b>						
(1) Current tax	95.79	75.53	63.87	171.32	120.42	219.42
(2) Income tax of earlier years	-	-	1.15	-	1.15	1.15
(3) Reversal of MAT credit entitlement of earlier years	-	-	-	-	-	-
(4) Deferred tax-(Net)	(7.17)	7.46	2.09	0.29	(0.38)	(7.10)
<b>Total tax expense (VIII)</b>	<b>88.62</b>	<b>82.99</b>	<b>67.12</b>	<b>171.61</b>	<b>121.19</b>	<b>213.47</b>
<b>IX Net Profit/(loss) after tax (VII-VIII)</b>	<b>210.45</b>	<b>156.07</b>	<b>159.26</b>	<b>366.51</b>	<b>291.65</b>	<b>641.74</b>
<b>X Other Comprehensive Income</b>						
A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
B (i) Items that will be reclassified to profit or loss	-	-	(0.86)	-	(0.86)	3.05
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	0.57	-	0.25	(0.62)
<b>Other comprehensive income for the period</b>	-	-	<b>(0.29)</b>	-	<b>(0.61)</b>	<b>2.43</b>
<b>XI Total comprehensive income for the period (IX+X) (Comprising Profit (Loss) and Other comprehensive income for the period)</b>	<b>210.45</b>	<b>156.07</b>	<b>158.97</b>	<b>366.51</b>	<b>291.04</b>	<b>644.17</b>
<b>XII Earnings Per Share (Face Value of Rs.10 each) (Not Annualised for the Quarter/half year ended)</b>						
Basic	2.90	2.38	2.43	5.04	4.44	9.83
Diluted	2.90	2.38	2.43	5.04	4.44	9.83
Paid up Equity Share Capital (Equity Share of Face Value Rs. 10/- each)	858.50	655.17	655.17	858.50	655.17	655.17

For the quarter/ Half Year ended on 30th September, 2023 EPS is calculated based on Weighted Average Number of Shares.



YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITED  
 UNAUDITED STANDALONE STATEMENT OF CASH FLOW FOR THE PERIOD ENDED SEP 30, 2023

(all amounts in Rs. millions, unless otherwise stated)

Particulars	Figures for the period ended Sep 30, 2023	Figures for the year ended March 31, 2023	Figures for the period ended Sep 30, 2022
Cash flow from operating activities			
Profit before tax and exceptional items	538.12	855.21	412.84
<b>Adjustments for:</b>			
Depreciation and Amortisation expense	63.25	126.45	55.99
Finance costs	39.89	87.37	37.26
Interest on Bank deposits	(29.27)	(0.55)	(0.15)
<b>Operating profit before working capital changes</b>	<b>611.99</b>	<b>1,068.47</b>	<b>505.94</b>
<b>Working capital adjustments</b>			
(Increase)/Decrease in Trade receivables	(406.97)	(94.93)	(107.72)
(Increase)/Decrease in Inventories	(0.40)	(8.68)	(13.44)
(Increase)/Decrease in Financial Assets and other Current and Non-Current Assets	238.19	(193.29)	(44.52)
Increase (Decrease) in Financial Liabilities & Other Current and Non-Current Liabilities	9.11	(199.01)	35.43
Increase (Decrease) in Short Term and Long Term Provisions	2.62	5.24	2.29
<b>Cash generated from operations</b>	<b>454.54</b>	<b>577.81</b>	<b>377.98</b>
Income tax (paid)/Refund (net)	(163.45)	(321.99)	(95.00)
<b>Net cash inflow from (used in) operating activities----'A'</b>	<b>291.09</b>	<b>255.82</b>	<b>282.98</b>
<b>Cash flow from Investing activities</b>			
Purchase of Property, plant and equipment including capital work in progress and capital advances and capital creditors	(184.40)	(84.75)	(80.20)
Investment in Subsidiary	-	-	-
Interest on Bank deposits	29.27	0.55	0.15
Investment in bank deposits having original maturity of more than three months	(2,200.32)	(2.41)	(1.97)
<b>Net cash used in investing activities-----'B'</b>	<b>(2,355.45)</b>	<b>(86.62)</b>	<b>(82.02)</b>
<b>Cash flow from Financing activities</b>			
Issue of share including premium net of issue expenses	5,768.77	-	-
Payment of loans of subsidiary companies	(1,910.46)	-	-
Interest & financial charges paid	(39.89)	(87.37)	(37.26)
Net Movement of Long Term Borrowings and short term borrowings	(1,071.40)	44.31	(147.81)
Payment of lease liability	(10.10)	(19.49)	(9.63)
<b>Net cash used in financing activities----'C'</b>	<b>2,736.92</b>	<b>(62.54)</b>	<b>(194.70)</b>
Net increase/(Decrease) in cash or cash equivalent (A+B+C)	672.56	106.65	6.27
Cash & cash equivalent at the commencement of the period	121.55	14.90	14.90
<b>Cash &amp; cash equivalent at the end of the period</b>	<b>794.11</b>	<b>121.55</b>	<b>21.17</b>
Reconciliation of cash and cash equivalents as per the cash flow statement			
Balance with banks in current accounts	240.17	106.88	17.17
Cash in hand	0.78	12.60	3.48
Bank Deposits with maturing with in 3 months	553.17	2.08	0.52
<b>Total</b>	<b>794.11</b>	<b>121.55</b>	<b>21.17</b>



**Notes to accounts on the unaudited standalone financial results of Yatharth Hospital & Trauma Care Services Limited for the quarter and half year ended September 30<sup>th</sup> 2023:**

1. The unaudited standalone financial results ('the Statement') of Yatharth Hospital & Trauma Care Services Limited for the quarter and half year ended September 30, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 7, 2023. The Statement was subjected to limited review by the statutory auditors, R. Nagpal Associates, Chartered Accountants and the review report is unmodified.
2. The Statement has been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 'Interim Financial Reporting' specified under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other Generally Accepted Accounting Principles in India.
3. The Chief operating decision maker (CODM- CEO) examines the Group's performance from revenue perspective and identifies 'Medical and Healthcare Services' as the only business revenue segment. The group operates in India and it constitutes the single geographical segment.
4. The figures for the quarter ended September 30<sup>th</sup> 2022 represents the difference between the unaudited figures in respect of period ended September 30<sup>th</sup> 2022 and the un-audited figures in respect of period ended September 30<sup>th</sup> 2022.
5. During the current year FY 2023-24, the Company had undertaken a Pre-IPO Placement by way of private placement of 4,000,000 Equity Shares for cash at a price of ₹ 300 per Equity Share aggregating to ₹ 1,200.00 million, in consultation with the BRLMs, pursuant to the resolution of the Board dated July 6, 2023. Further the Company had completed its Initial Public Offer (IPO) Fresh issue of 16,333,333 ("Fresh Issue") Equity Shares aggregating to ₹ 4,900.00 million and Offer for sale of 6,551,690 ("Offer for Sale") Equity Shares aggregating to ₹ 1,965.51 million by the Selling Shareholders. Put together the size of the Fresh Issue (Including Pre IPO) of Equity Shares had been ₹ 6,100.00 million. The Company got listed on National Stock Exchange of India and BSE Ltd on 7<sup>th</sup> August 2023.

The utilization of the IPO proceeds is summarized below:

Object of the Issue as per prospectus	Utilisation planned as per Prospectus	(Amount in Million)	
		Utilised upto 30-09-2023	Amount pending for utilization as on 30-09-2023*
Repayment/ prepayment, in full or part, of borrowings availed by Yatharth Hospital & Trauma Care Services Ltd ("Yatharth").	1000.00	1000.00	0.00



Repayment/ prepayment, in full or part, of borrowings availed by Subsidiaries of Yatharth; namely, AKS Medical & Research Centre Private Limited ("AKS") and Ramraja Multispeciality Hospital & Trauma Centre Private Limited ("Ramraja")	1450.00	1427.19	22.81
Funding capital expenditure expenses of Yatharth for two hospitals, namely, Noida Hospital and Greater Noida Hospital	256.44	24.88	231.56
Funding capital expenditure expenses of Subsidiaries of Yatharth; namely AKS and Ramraja, for the respective hospital operated by them	1069.66	33.39	1036.27
Funding inorganic growth initiatives through acquisitions and other strategic initiatives	650.00	0.00	650.00
General corporate purposes	1271.00	283.21	987.79
IPO Issue Expense **	402.90	331.23	71.67
<b>Total</b>	<b>6100.00</b>	<b>3099.90</b>	<b>3000.10</b>

\*- a portion of the un-utilized proceeds have temporarily been invested in the term deposits with scheduled banks.

\*\* - Only the portion of issue expense belonging to the Company

6. The income tax department conducted searches under section 132 of the Income tax act at the premises belonging to the holding company, subsidiary companies and the key managerial persons of the Company. The Company provided necessary information and data, as required by the Income Tax department and provided the fullest co-operation. The Income tax department took data back-ups and other information. The business operations of the Company continued without any disruptions and the department has so far not raised any income tax demand. The Company shall continue to provide the required co-operation and information to the department and is confident that this search will not cause any additional tax liability on the Company. The Income tax department has seized Rs 86 lacs ( Rupee eighty six lacs) out of operational cash belonging to Yatharth group and the Company is confident that the same shall be returned, in due course of time.
7. The aforesaid Statement is available on the Holding Company's website ([www.yatharthhospitals.in](http://www.yatharthhospitals.in)) and on the website of the Stock Exchanges ([www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) ).




On behalf of the Board of Directors  
Yatharth Hospital & Trauma Care Services Ltd.

  
Dr. Ajay Kumar Tyagi  
Chairman and Whole-time Director

Place: Noida

Dated: 07/11/2023









Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of Yatharth Hospital & Trauma Care Services Limited pursuant to Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

**To the Board of Directors of  
Yatharth Hospital & Trauma Care Services Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated financial results of **Yatharth Hospital & Trauma Care Services Limited** (the Holding Company) and its subsidiaries (The Holding Company and its Subsidiaries together referred to as 'the Group') for the quarter and Half year ended 30<sup>th</sup> September 2023 together with the notes thereon (hereinafter referred to as "the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("IND AS 34"), prescribed under section 133 of the Companies Act, 2013 as amended read with relevant rules issued thereunder and other accounting principles generally accepted in India and is in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditors of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of



persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulation, to the extent applicable.

4. The Statement includes the results of the following Subsidiaries:

(i) AKS Medical & Research Centre Private Limited

(ii) Ramraja Multispeciality Hospital & Trauma Centre Private Limited

(iii) Sanskar Medica India Limited

5. Other Matters

We did not review the financial results of Three subsidiaries included in the consolidated financial results whose financial results reflect total assets of Rs.2,506.84 as at 30<sup>th</sup> September 2023, Total revenues of Rs.521.63 Millions, and Rs1,133.20 Millions for the quarter and half year ended 30<sup>th</sup> Sept 2023 respectively , total Net Profit after tax of Rs.34.29 Millions and Rs.99.87 Millions for the quarter and half year ended 30<sup>th</sup> Sept 2023 respectively and total comprehensive income of Rs. 34.29 Millions and Rs. 99.87 Millions for the quarter and half year ended 30<sup>th</sup> Sept 2023 respectively as considered in the consolidated unaudited financial results. These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our Conclusion on above matter is not modified.

6. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statements prepared in accordance with the recognition and measurement principles laid down in IND AS 34, prescribed under section 133 of the Act as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information



required to be disclosed in accordance with the requirement of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatements

For R. Nagpal Associates  
Chartered Accountants  
Firm Registration No. 002626N

(CA. Rohit Mehra)  
Partner  
Membership No. 093910



UDIN: 23093910BGUGKD2688  
Place: Noida  
Date: 07<sup>th</sup> November 2023

# YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITED

UNAUDITED CONSOLIDATED BALANCE SHEET AS AT SEP 30, 2023

(all amounts in Rs. millions, unless otherwise stated)

Particulars	As at Sep 30, 2023	As at March 31, 2023
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, Plant and Equipment	2,472.04	2,553.09
Capital work in progress	56.05	-
Right-of-use of assets	24.59	35.12
Goodwill	397.01	397.01
Financial Assets		
(i) Other Financial Assets	15.82	19.56
Deferred Tax Assets (Net)	79.29	82.79
Other Non Current Assets	176.15	9.41
<b>Total non-current assets</b>	<b>3,220.96</b>	<b>3,096.98</b>
<b>Current assets</b>		
Inventories	59.36	60.70
Financial Assets		
(i) Trade receivables	1,741.41	1,076.44
(ii) Cash and cash equivalents	857.53	374.32
(iii) Bank Balance other than (ii) above	2,382.79	10.11
Current Tax assets (Net)	117.77	111.78
Other Current assets	162.23	129.31
<b>Total current assets</b>	<b>5,321.09</b>	<b>1,762.67</b>
<b>Total Assets</b>	<b>8,542.05</b>	<b>4,859.66</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Equity Share Capital	858.50	655.17
Other Equity	7,206.29	1,174.47
<b>Equity attributable to the owners of the company</b>	<b>8,064.79</b>	<b>1,829.64</b>
Non-controlling interest	-	-
<b>Total Equity</b>	<b>8,064.79</b>	<b>1,829.64</b>
<b>Non-current liabilities</b>		
Financial liabilities		
(i) Borrowings	29.16	2,005.94
(ii) Lease Liabilities	5.31	15.91
Provisions	16.87	12.99
Deferred tax liabilities (Net)	-	-
<b>Total non-current liabilities</b>	<b>51.33</b>	<b>2,034.84</b>
<b>Current liabilities</b>		
Financial liabilities		
(i) Borrowings	76.12	631.82
(ii) Lease Liabilities	20.95	20.45
(iii) Trade payables		
(a) Total outstanding dues of Micro Enterprises and Small Enterprises	21.26	15.08
(b) Total outstanding dues of creditors other than Micro Enterprises and Small Enterpri	124.72	153.69
(iv) Other financial liabilities	161.74	142.40
Other current liabilities	20.56	31.15
Provisions	0.59	0.59
<b>Total current liabilities</b>	<b>425.93</b>	<b>995.18</b>
<b>Total Equity and Liabilities</b>	<b>8,542.05</b>	<b>4,859.66</b>



# YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITED

Regd. Office : JA 108 DLF Tower A NA Jasola District Centre South Delhi DL 110025 India

Corporate Office: HO-01, Sector-1 Greater Noida West Gautam Buddha Nagar UP 201306 India

Website: www.yatharthhospitals.com

Email: cs@yatharthhospitals.com

CIN : U85110DL2008PLC174706

## STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER/ HALF YEAR ENDED 30TH SEPTEMBER, 2023

(Rs. in Million except Shares and EPS)

Particulars	CONSOLIDATED					
	Quarter Ended			Half Year Ended		Year Ended (Audited)
	30 Sep'2023	30 June'2023	30 Sep'2022	30 Sep'2023	30 Sep'2022	31 March'2023
<b>I</b> Revenue from operations	1,712.80	1,545.07	1,278.89	3,257.86	2,389.56	5,202.93
<b>II</b> Other income	38.21	7.57	7.45	45.77	13.30	28.07
<b>III</b> Total Income (I+II)	<b>1,751.00</b>	<b>1,552.63</b>	<b>1,286.34</b>	<b>3,303.64</b>	<b>2,402.86</b>	<b>5,231.00</b>
<b>IV</b> Expenses						
Medical consumables and pharmacy items consumed	360.47	280.52	230.99	640.98	443.91	929.35
Employee benefits expense	283.93	268.38	237.35	552.31	432.70	919.30
Finance costs	29.41	59.29	49.80	88.71	94.76	213.87
Depreciation and amortisation	68.79	68.74	62.79	137.53	123.48	275.07
Other expenses	612.70	582.02	475.32	1,194.73	920.89	2,016.63
<b>Total expenses (IV)</b>	<b>1,355.30</b>	<b>1,258.95</b>	<b>1,056.25</b>	<b>2,614.25</b>	<b>2,015.74</b>	<b>4,354.22</b>
<b>V</b> Profit / (loss) before exceptional items and tax (III-IV)	<b>395.70</b>	<b>293.68</b>	<b>230.10</b>	<b>689.39</b>	<b>387.13</b>	<b>876.78</b>
<b>VI</b> Exceptional items (net)(Gain)/Loss	-	-	-	-	-	-
<b>VII</b> Profit / (loss) before tax (V-VI)	<b>395.70</b>	<b>293.68</b>	<b>230.10</b>	<b>689.39</b>	<b>387.13</b>	<b>876.78</b>
<b>VIII</b> Tax expense						
(1) Current tax	116.91	102.59	71.60	219.50	130.26	246.65
(2) Income tax of earlier years	-	-	1.15	-	1.15	1.61
(3) Reversal of MAT credit entitlement of earlier years	4.88	-	(0.82)	4.88	-	11.02
(4) Deferred tax- (Net)	(2.11)	0.73	(5.46)	(1.38)	(16.24)	(40.19)
<b>Total tax expense (VIII)</b>	<b>119.68</b>	<b>103.32</b>	<b>68.11</b>	<b>223.00</b>	<b>115.17</b>	<b>219.10</b>
<b>IX</b> Net Profit/(loss) after tax (VII-VIII)	<b>276.03</b>	<b>190.36</b>	<b>161.99</b>	<b>466.39</b>	<b>271.95</b>	<b>657.68</b>
<b>X</b> Other Comprehensive Income						
A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
B (i) Items that will be reclassified to profit or loss	-	-	0.26	-	0.26	4.01
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	0.26	-	(0.06)	(0.90)
<b>Other comprehensive income for the period</b>	<b>-</b>	<b>-</b>	<b>0.52</b>	<b>-</b>	<b>0.20</b>	<b>3.11</b>
<b>XI</b> Total comprehensive income for the period (IX+X) (Comprising Profit (Loss) and Other comprehensive income for the period)	<b>276.03</b>	<b>190.36</b>	<b>162.52</b>	<b>466.39</b>	<b>272.16</b>	<b>660.80</b>
<b>Profit/(Loss) for the year attributable to:</b>						
To the Owners of the company	276.03	190.36	161.99	466.39	271.95	657.68
Non Controlling Interest	-	-	-	-	-	-
<b>Other comprehensive income for the period/year attributable to:</b>						
To the Owners of the company	-	-	0.52	-	0.20	3.11
Non Controlling Interest	-	-	-	-	-	-
<b>Total Comprehensive Income for the period attributable to:</b>						
To the Owners of the company	<b>276.03</b>	<b>190.36</b>	<b>162.52</b>	<b>466.39</b>	<b>272.16</b>	<b>660.80</b>
Non Controlling Interest	-	-	-	-	-	-
<b>XII</b> Earnings Per Share (Face Value of Rs.10 each) (Not Annualised for the Quarter/half year ended)						
Basic	3.80	2.91	2.48	6.42	4.15	10.09
Diluted	3.80	2.91	2.48	6.42	4.15	10.09
Paid up Equity Share Capital (Equity Share of Face Value Rs. 10/- each)	858.50	655.17	655.17	858.50	655.17	655.17

For the quarter/ Half Year ended on 30th September, 2023 EPS is calculated based on Weighted Average Number of Shares.



**YATHARTH HOSPITAL & TRAUMA CARE SERVICES LIMITED**  
**UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOW FOR THE PERIOD ENDED SEP 30, 2023**  
(all amounts in Rs. millions, unless otherwise stated)

Particulars	Figures for the period ended Sep 30, 2023	Figures for the year ended March 31, 2023	Figures for the period ended Sep 30, 2022
<b>Cash flow from operating activities</b>			
Profit/(Loss) before tax and exceptional items	689.38	876.78	387.13
<b>Adjustments for :</b>			
Depreciation and Amortisation expense	137.53	275.07	123.48
Finance costs	88.71	213.87	94.76
Interest on bank deposits	(31.10)	(1.41)	(0.85)
<b>Operating profit before working capital changes</b>	<b>884.51</b>	<b>1,364.30</b>	<b>604.52</b>
<b>Working capital adjustments</b>			
(Increase)/Decrease in Trade receivables	(664.96)	(221.06)	(132.01)
(Increase)/Decrease in Inventories	1.33	(8.74)	(21.52)
(Increase)/Decrease in Financial Assets and other Current and Non-Current Assets	(29.17)	(91.01)	(33.49)
Increase (Decrease) in Financial Liabilities & Other Current and Non-Current Liabilities	(14.07)	(39.43)	(64.37)
Increase (Decrease) in Current and Non current Provisions	3.88	7.75	4.04
<b>Cash generated from operations</b>	<b>181.51</b>	<b>1,011.81</b>	<b>357.17</b>
Income tax (paid)/Refund (net)	(225.49)	(373.98)	(117.31)
<b>Net cash inflow from operating activities----'A'</b>	<b>(43.98)</b>	<b>637.84</b>	<b>239.86</b>
<b>Cash flow from Investing activities</b>			
Purchase of Property, plant and equipment including capital work in progress and capital advances and capital creditors	(268.74)	(198.14)	(123.17)
Acquisition of Fixed Assets-Net of Liabilities On account of Business Combination	-	-	-
Investment in Subsidiary	-	-	-
Interest on Bank deposits	31.10	1.41	0.85
Investment in bank deposits having original maturity of more than three months	(2,372.67)	(6.37)	(1.95)
<b>Net cash used in investing activities-----'B'</b>	<b>(2,610.31)</b>	<b>(203.10)</b>	<b>(124.27)</b>
<b>Cash flow from Financing activities</b>			
Issue of share including premium net of share issue expenses	5,768.77	-	-
Net movement of long term borrowings and short term borrowings	(2,542.58)	36.39	(87.66)
Finance Cost	(88.71)	(213.87)	(94.76)
Payment of lease liability	-	-	-
<b>Net cash used in financing activities----'C'</b>	<b>(2,631.28)</b>	<b>(177.48)</b>	<b>(182.42)</b>
Net increase/(Decrease) in cash or cash equivalent (A+B+C)	483.20	257.25	(66.84)
Cash & cash equivalent at the commencement of the period	374.32	117.07	117.07
Add: On account of Business Combination	-	-	-
<b>Cash &amp; cash equivalent at the end of the period</b>	<b>857.53</b>	<b>374.32</b>	<b>50.23</b>
Reconciliation of cash and cash equivalents as per the cash flow statement			
Balance with banks in current accounts	282.32	356.80	36.49
Cash in hand	3.64	15.45	13.22
Bank Deposits with maturing with in 3 months	571.57	2.08	0.52
<b>Total</b>	<b>857.53</b>	<b>374.32</b>	<b>50.23</b>



*Asst*


**Notes to accounts on the unaudited consolidated financial results of Yatharth Hospital & Trauma Care Services Limited for the quarter and half year ended September 30<sup>th</sup> 2023:**

1. The unaudited consolidated financial results ('the Statement') of Yatharth Hospital & Trauma Care Services Limited ('the Holding Company') along with its subsidiaries for the quarter and half year ended September 30, 2023 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 7, 2023. The Statement was subjected to limited review by the statutory auditors, R. Nagpal Associates, Chartered Accountants and the review report is unmodified.
2. The Statement has been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 'Interim Financial Reporting' specified under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other Generally Accepted Accounting Principles in India.
3. The Chief operating decision maker (CODM- CEO) examines the Group's performance from revenue perspective and identifies 'Medical and Healthcare Services' as the only business revenue segment. The group operates in India and it constitutes the single geographical segment.
4. The figures for the quarter ended September 30<sup>th</sup> 2022 represents the difference between the unaudited figures in respect of period ended September 30<sup>th</sup> 2022 and the un-audited figures in respect of period ended June 30<sup>th</sup> 2022.
5. During the current year FY 2023-24, Company had undertaken a Pre-IPO Placement by way of private placement of 4,000,000 Equity Shares for cash at a price of ₹ 300 per Equity Share aggregating to ₹ 1,200.00 million, in consultation with the BRLMs, pursuant to the resolution of the Board dated July 6, 2023. Further the Company had completed its Initial Public Offer (IPO) Fresh issue of 16,333,333 ("Fresh Issue") Equity Shares aggregating to ₹ 4,900.00 million and Offer for sale of 6,551,690 ("Offer for Sale") Equity Shares aggregating to ₹ 1,965.51 million by the Selling Shareholders. Put together the size of the Fresh Issue (Including Pre IPO) of Equity Shares had been ₹ 6,100.00 million. The Company got listed on National Stock Exchange of India and BSE Ltd on 7<sup>th</sup> August 2023.

The utilization of the IPO proceeds is summarized below:

(Amount in Million)

Object of the Issue as per prospectus	Utilisation planned as per Prospectus	Utilised upto 30-09-2023	Amount pending for utilization as on 30-09-2023*
Repayment/ prepayment, in full or part, of borrowings availed by Yatharth Hospital & Trauma Care Services Ltd ("Yatharth").	1000.00	1000.00	0.00



Repayment/ prepayment, in full or part, of borrowings availed by Subsidiaries of Yatharth; namely, AKS Medical & Research Centre Private Limited ("AKS") and Ramraja Multispeciality Hospital & Trauma Centre Private Limited ("Ramraja")	1450.00	1427.19	22.81
Funding capital expenditure expenses of Yatharth for two hospitals, namely, Noida Hospital and Greater Noida Hospital	256.44	24.88	231.56
Funding capital expenditure expenses of Subsidiaries of Yatharth; namely AKS and Ramraja, for the respective hospital operated by them	1069.66	33.39	1036.27
Funding inorganic growth initiatives through acquisitions and other strategic initiatives	650.00	0.00	650.00
General corporate purposes	1271.00	283.21	987.79
IPO Issue Expense **	402.90	331.23	71.67
<b>Total</b>	<b>6100.00</b>	<b>3099.90</b>	<b>3000.10</b>

\* - a portion of the un-utilized proceeds have temporarily been invested in the term deposits with scheduled banks.

\*\* - Only the portion of issue expense belonging to the Company

6. The income tax department conducted searches under section 132 of the Income tax act at the premises belonging to the holding company, subsidiary companies and the key managerial persons of the Company. The Company provided necessary information and data, as required by the Income Tax department and provided the fullest co-operation. The Income tax department took data back-ups and other information. The business operations of the Company continued without any disruptions and the department has so far not raised any income tax demand. The Company shall continue to provide the required co-operation and information to the department and is confident that this search will not cause any additional tax liability on the Company. The Income tax department has seized Rs 86 lacs ( Rupee eighty six lacs) out of operational cash belonging to Yatharth group and the Company is confident that the same shall be returned, in due course of time.
7. The aforesaid Statement is available on the Holding Company's website ([www.yatharthhospitals.in](http://www.yatharthhospitals.in)) and on the website of the Stock Exchanges ([www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) ).



On behalf of the Board of Directors  
Yatharth Hospital & Trauma Care Services Ltd.

*Aj*  
Dr. Ajay Kumar Tyagi  
Chairman and Whole-time Director

Place: Noida

Dated: 07/11/2023



*Aj*